一般演題3-15C AML：ゲノム解析

[OS3-15C-4] The role of NGS-based MRD status at CR1 for selecting consolidation therapy in normal karyotype AML

TaeHyung Kim^1,2, Jae-Sook Ahn^1,3,4, Sung-Hoon Jung³, Seo-Yeon Ahn³, Seung-Yeon Jung³, Deok-Hwan Yang³, Je-Jung Lee³, SeungHyun Choi⁴, Ja-Yeon Lee⁴, Seong-Kyu Park⁵, Hui Young Lee^6,7, Kyoungha Kim^7,8, Yu Cai^7,9, Zhaolei Zhang^1,2,10, Hyeoung-Joon Kim^3,4, Dennis Dong Hwan Kim⁷ (1.The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada, 2.Department of Computer Science, University of Toronto, Toronto, Ontario, Canada, 3.Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea, 4.Genomic Research Center for Hematopoietic Diseases, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea, 5.Department of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Republic of Korea, 6.Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Gangwon-do, Republic of Korea, 7.Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada, 8.Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Seoul, Republic of Korea, 9.Department of Hematology, Shanghai General Hospital affiliated to Shanghai Jiaotong University, Shanghai, Shanghai, People's Republic of China, 10.Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada)